WO1998024808A3 - Inhibition d'allergies provoquees par l'immunoglobuline e grace a un oligopeptide derive de l'immunoglobuline e humaine - Google Patents

Inhibition d'allergies provoquees par l'immunoglobuline e grace a un oligopeptide derive de l'immunoglobuline e humaine Download PDF

Info

Publication number
WO1998024808A3
WO1998024808A3 PCT/US1997/022348 US9722348W WO9824808A3 WO 1998024808 A3 WO1998024808 A3 WO 1998024808A3 US 9722348 W US9722348 W US 9722348W WO 9824808 A3 WO9824808 A3 WO 9824808A3
Authority
WO
WIPO (PCT)
Prior art keywords
ige
human ige
peptides
inhibition
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/022348
Other languages
English (en)
Other versions
WO1998024808A2 (fr
WO1998024808B1 (fr
WO1998024808A9 (fr
Inventor
Eduardo A Padlan
A Helm Birgit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU65324/98A priority Critical patent/AU6532498A/en
Publication of WO1998024808A2 publication Critical patent/WO1998024808A2/fr
Publication of WO1998024808A3 publication Critical patent/WO1998024808A3/fr
Publication of WO1998024808A9 publication Critical patent/WO1998024808A9/fr
Publication of WO1998024808B1 publication Critical patent/WO1998024808B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des peptides capables de reconnaître effectivement le récepteur Fcε de l'immunoglobuline E humaine. Les peptides comprennent en partie un fragment d'immunoglobuline E humaine. En ajoutant des résidus d'acides aminés de contrainte aux terminaisons N et C des polypeptides ou près de ces terminaux, on peut forcer ces peptides à présenter une configuration en boucle. Ces peptides contraints s'utilisent comme concurrents de l'immunoglobuline E humaine pour le récepteur Fcε et peuvent s'utiliser pour bloquer le développement d'une hypersensibilité de type I.
PCT/US1997/022348 1996-12-06 1997-12-05 Inhibition d'allergies provoquees par l'immunoglobuline e grace a un oligopeptide derive de l'immunoglobuline e humaine Ceased WO1998024808A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65324/98A AU6532498A (en) 1996-12-06 1997-12-05 Inhibition of ige-mediated allergies by a human ige-derived oligopeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3199196P 1996-12-06 1996-12-06
US60/031,991 1996-12-06

Publications (4)

Publication Number Publication Date
WO1998024808A2 WO1998024808A2 (fr) 1998-06-11
WO1998024808A3 true WO1998024808A3 (fr) 1998-08-13
WO1998024808A9 WO1998024808A9 (fr) 1998-10-08
WO1998024808B1 WO1998024808B1 (fr) 1998-11-12

Family

ID=21862518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022348 Ceased WO1998024808A2 (fr) 1996-12-06 1997-12-05 Inhibition d'allergies provoquees par l'immunoglobuline e grace a un oligopeptide derive de l'immunoglobuline e humaine

Country Status (2)

Country Link
AU (1) AU6532498A (fr)
WO (1) WO1998024808A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801722T2 (xx) 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
WO2000050460A1 (fr) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes ou mimotopes derives du domaine c-epsilon-2 de l'immoglobuline e, leurs antagonistes et leurs applications therapeutiques
EP1155038A1 (fr) * 1999-02-25 2001-11-21 SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
EP1195161A3 (fr) 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccins
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
CN107469064A (zh) * 2016-06-08 2017-12-15 广州艾玫格生物科技有限公司 生物抗敏复合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (fr) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Nouveaux systemes d'administration de medicaments a base de lipoproteines
WO1989004834A1 (fr) * 1987-11-19 1989-06-01 Research Corporation Limited Agent concurrent de l'immunoglobuline e
WO1995020606A1 (fr) * 1994-01-26 1995-08-03 Pasteur Merieux Serums Et Vaccins Vaccin anti-allergique
WO1995025957A1 (fr) * 1994-03-18 1995-09-28 Merck & Co., Inc. ANTAGONISTES ET AGONISTES DE C5a HUMAIN

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (fr) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Nouveaux systemes d'administration de medicaments a base de lipoproteines
WO1989004834A1 (fr) * 1987-11-19 1989-06-01 Research Corporation Limited Agent concurrent de l'immunoglobuline e
WO1995020606A1 (fr) * 1994-01-26 1995-08-03 Pasteur Merieux Serums Et Vaccins Vaccin anti-allergique
WO1995025957A1 (fr) * 1994-03-18 1995-09-28 Merck & Co., Inc. ANTAGONISTES ET AGONISTES DE C5a HUMAIN

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B.A. HELM ET AL: "Identification of the high affinity receptor binding region in human immunoglobulin E", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, no. 13, 29 March 1996 (1996-03-29), MD US, pages 7494 - 7500, XP002067058 *
GHADERI ET AL: "Epitope mapping of the sites of binding of Fc epsilon within human IgE", MOLECULAR IMMUNOLOGY, vol. 30, no. 18, 1993, pages 1655 - 1663, XP002067059 *
NIO N ET AL: "INHIBITION OF ALLERGIC RESPONSES BY SYNTHETIC IMMUNOGLOBULIN E PEPTIDE FRAGMENTS AND THE DELINEATION OF THE BINDING SITES IN THE IMMUNOGLOBULIN E MOLECULE TO THE FC RECEPTOR", PEPTIDE CHEMISTRY, PROCEEDINGS 29TH SYMPOSIUM ON PEPTIDE CHEMISTRY, TOKYO, OCT. 24-26, 1991, 1987, pages 765 - 768, XP000654192 *
WANG Y: "PEPTIDES DERIVED FROM IG HEAVY CHAIN CONSTANT REGION INDUCE PROFOUND IGE ISOTYPE-SPECIFIC TOLERANCE", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 5, May 1996 (1996-05-01), pages 1043 - 1049, XP000645198 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Also Published As

Publication number Publication date
WO1998024808A2 (fr) 1998-06-11
AU6532498A (en) 1998-06-29

Similar Documents

Publication Publication Date Title
AU4188789A (en) Urethane-protected amino acid-n-carboxyanhydrides
TR199501669A1 (tr) Peptid ve proteinlerin aerosol formülasyonlari.
EP1619202A3 (fr) procedes immunotherapeutiques utilisant des epitopes de wt-1 et gata-1
WO1995007992A3 (fr) Decarboxylase d'acide glutamique clonee
DE69739219D1 (de) Peptide und zusammensetzungen, die an den thrombopoietin-rezeptor binden
WO2001000666A3 (fr) Peptides s'alignant automatiquement construits sur le modele de l'elastine humaine et d'autres proteines fibreuses
AU4397297A (en) Antibody against human parathormone related peptides
ZW17893A1 (en) Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof.
CA2111645A1 (fr) Peptides e a fragment fibrinogene et leurs anticorps
WO1998005685A3 (fr) Peptides s'alignant automatiquement et derives de l'elastine et d'autres proteines fibreuses
DE59610649D1 (de) Osteosynthetisches befestigungselement
WO1998024808A3 (fr) Inhibition d'allergies provoquees par l'immunoglobuline e grace a un oligopeptide derive de l'immunoglobuline e humaine
WO2000075173A3 (fr) Peptides
GR3036979T3 (en) Coupling product obtained from hystamine and an amino acid.
DE69326255D1 (de) Elam-1 bindende peptide und zusammensetzungen
BR9712067A (pt) Pept¡dios imunog-nicos de v¡rus da doen-a de febre aftosa
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
DE69528667D1 (de) Verwendung von vom pban(1-33)nh2 abstammende peptidfragmente zur entwurf von pban-antagonisten zur bekämpfung von motten
KR950703058A (ko) 일본 삼목 꽃가루로 부터의 알레르겐 유발성 단백질 및 펩타이드(allergenic proteins and peptides from japanese cedar pollen)
EP0846950A3 (fr) Peptides utiles comme standards internes pour le microséquençage et procédé pour les utiliser
CA2173939A1 (fr) Oligopeptides derives de fragments de proteines c-reactives
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
GB9705519D0 (en) Activation of peptides
WO2001078796A3 (fr) Recepteur de la gonadoliberine de type ii et polynucleotides codant pour ce recepteur
AU2161699A (en) Peptides and nucleic acids derived from (eisenia foetida) and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase